Introduction
============

The Hopkins Lupus Cohort is a longitudinal study in which all SLE patients are seen quarterly, by protocol, by one rheumatologist. The specific aims include prevention of organ damage. In this abstract, two projects - noncalcified plaque (NCP) and treatment of antiphospholipid antibodies - will be reviewed.

Methods
=======

For the study on NCP, 64-slice (*n*= 106) or 320-slice (*n*= 121) coronary multidetector computed tomography (MDCT) was performed in 227 patients with SLE. The MDCT scans were evaluated quantitatively by a radiologist, using dedicated software. The NCP score was a sum of plaque severity multiplied by the plaque composition divided by the number of vessels examined.

For the study on treatment of antiphospholipid antibodies, we studied 1,795 SLE patients (56% Caucasian, 37% African American, 93.3% female, mean age 37.0 ± 12.5) with no previous thrombosis prior to entry in the cohort. The primary outcome was first thrombotic event (arterial or venous). Univariate analysis and multivariable modeling were used to examine associations between prednisone, hydroxycholoquine, and NSAID use with the risk of thrombosis.

Results
=======

The multiple regression model for the mean level of NCP is shown in Table [1](#T1){ref-type="table"}. The multiple regression model for prevention of thrombosis is presented in Table [2](#T2){ref-type="table"}.

  Variable                Effect on mean NCP score (95% CI)   *P*value
  ----------------------- ----------------------------------- ----------
  Age (per 10 years)      0.085 (0.057 to 0.113)              \<0.0001
  Low BMI (vs. normal)    -0.096 (-0.175 to -0.018)           0.017
  High BMI (vs. normal)   0.002 (-0.080 to 0.084)             0.96
  Hypertension            0.065 (-0.005 to 0.136)             0.068
  History of low C3       0.090 (0.020 to 0.161)              0.012
  History of ant-dsDNA    0.031 (-0.042 to 0.103)             0.40
  Male sex                0.087 (-0.017 to 0.191)             0.10
  Methotrexate current    0.279 (0.113 to 0.445)              0.0011

                               Subgroup                    Thrombotic events   Rate of events/1,000 person-years   Rate ratios (95% CI)   *P*value
  ---------------------------- --------------------------- ------------------- ----------------------------------- ---------------------- ----------
  Current prednisone           None                        52                  10.6                                1.0 (Ref. Gp)          
                               1 to 9 mg/day               40                  16.4                                1.6 (1.1 to 2.4)       0.025
                               10 to 19 mg/day             49                  34.3                                3.3 (2.2 to 4.8)       \<0.0001
                               20+ mg/day                  43                  71.8                                6.5(4.3 to 9.8)        \<0.0001
  Cumulative prednisone dose   None                        29                  13.1                                1.0 (Ref. Gp)          
                               \<1 year (10 mg/day)        37                  23.8                                1.6 (1.0 to 2.6)       0.075
                               1 to 3 years (10 mg/day)    30                  19.0                                1.8 (1.1 to 3.1)       0.026
                               3 to 10 years (10 mg/day)   45                  25.5                                3.0 (1.8 to 5.2)       \<0.0001
                               \>10 years (10 mg/day)      9                   24.3                                3.7 (1.5 to 9.4)       0.0056
  Current HCQ                  No                          95                  29.0                                1.0 (Ref. Gp)          
                               Yes                         90                  14.6                                0.5 (0.4 to 0.7)       \<0.0001
  HCQ use                      Never                       57                  32.2                                1.0 (Ref. Gp)          
                               Past (not current)          27                  27.6                                0.9 (0.6 to 1.5)       0.81
                               \<6 consecutive months      16                  20.0                                0.6 (0.3 to 1.0)       0.056
                               \>6 consecutive months      64                  13.8                                0.5 (0.3 to 0.7)       0.0003
  NSAID use                    No                          146                 21.6                                1.0 (Ref. Gp)          
                               Yes                         37                  13.9                                0.6 (0.4 to 0.9)       0.017
  Aspirin use                  No                          137                 17.9                                1.0 (Ref. Gp)          
                               Yes                         49                  28.0                                1.6 (1.2 to 2.3)       0.0038

Conclusion
==========

For NCP, methotrexate increased NCP, possibly via homocysteine. For thrombosis, hydroxychloroquine significantly reduced thrombosis, but prednisone increased it. SLE longitudinal cohorts can address many clinical questions that are not suitable for clinical trials.
